Alogliptin approved for use in Wales
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): alogliptin, in combination with metformin or a sulphonylurea, to treat adults with type 2 diabetes (Vipdomet — a combination tablet containing metformin and alogliptin — is also approved); bortezomib, with dexamethasone, to treat adults with progressive multiple myeloma who have received at least one previous treatment and for whom haematopoietic stem cell transplantation has already been tried or is unsuitable; certolizumab for active psoriatic arthritis or severe active axial spondyloarthritis (provided the approved patient access scheme is used). Full details of the restrictions are available on the AWMSG website. Colestilan, a treatment for hyperphosphataemia in dialysis patients, is not recommended.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067049
Recommended from Pharmaceutical Press